Core Laboratories NV Stock News

Core Laboratories Inc. (NYSE:CLB ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Sean Mitchell - Daniel Energy Partners Operator Good day, and welcome to t...

REVENUE OF $123.6 MILLION, DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAR OPERATING INCOME OF $4.4 MILLION; EX-ITEMS, $11.8 MILLION, DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAR OPERATING MARGINS, EX-ITEMS, OF 10% GAAP EPS OF $0.00; EX-ITEMS, $0.14, DOWN 35% SEQUENTIALLY, AND 25% YEAR-OVER-YEAR FREE CASH FLOW OF $3.9 MILLION, UP OVER 50% YEAR-OVER-YEAR NET DEBT REDUCED BY $4.9 MILLION; DEBT LEVERAG...

HOUSTON, March 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its first quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on April 24, 2025.

Core Laboratories Inc. (NYSE:CLB ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Josh Jayne - Daniel Energy Partners David Smith - Pickering Energy Partn...

FOURTH QUARTER REVENUE OF $129.2 MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY YEAR-OVER-YEAR FOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4% YEAR-OVER-YEAR FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12%  FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.22, DOWN 12% SEQUENTIALLY, UP 16% YEAR-OVER-YEAR FOURTH QUARTER FREE CASH FLOW OF $16...

HOUSTON , Jan. 3, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2024 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m.

Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine,...